CytoTools AG reported on the expected successful course of the current dosage determination trial of DermaPro in phase II. Accordingly, recruitment and treatment of the first 100 patients has been completed successfully. As planned, an intermediate evaluation was carried out and these interim findings confirm that the dosage determination trial can continue and be terminated as scheduled. During theintermediate evaluation, the trial continued so that now already 140 from a total of 200 patients have been included. From today's perspective, all the required patients should be recruited before the end of April, and from this time onward, the treatment can be concluded within a maximum of 12 weeks. At the same time, the decisive phase III trial is being prepared. Its ultimate design will be decided depending on the final results of the dosage determination trial. If it is confirmed here that the phase III trial in Europe (diabetic foot syndrome), beginning from the third quarter 2019, can be carried out with such a comparatively low expenditure, the management board will intensify the search for a partner already in 2020. Further increase in the share of subsidiary DermaTools Biotech GmbH. Within the scope of a cash capital increase for the sum of about 1.7 million EUR, the CytoTools AG increased its share in DermaTools Biotech GmbH from almost 60 % to 62 %, thus simultaneously providing the financial means for achieving the next clinical targets. DermaTools can therefore continue to concentrate fully on the development of DermaPro.